[Red Yeast Rice Incident Research Report] The Choice of Industrially Mutated Strains Questioned by a Millennium of Red Yeast Rice Culture — Kobayashi Pharmaceutical Did Not Distinguish Between Strains with a Thousand Years of Dietary History and Those Without —
NQ Score
0/100
N1 Content Completeness
8
AI Summary (NQ-processed)
On June 9, 2026, Kunsei Club Co., Ltd. published a research report on the Kobayashi Pharmaceutical red yeast rice (beni-koji) health supplement incident. The report argues that the NITE BP-412 strain used in the product is an industrially mutated strain genetically distinct from traditional red yeast rice molds, and that Kobayashi Pharmaceutical's product design, which treated both as identical, had a structural flaw.
AI Analysis
Frequently Asked Questions
- Q: What is the main content of this research report?
- A: It points out that the NITE BP-412 strain used in Kobayashi Pharmaceutical's product is an industrial mutant strain different from traditional red yeast rice, and examines the problem of equating the two.
- Q: How was the NITE BP-412 strain created?
- A: According to Gunze's published patent (JP2009095304A), it is an industrially bred strain created by mutagenesis of Monascus pilosus NBRC4520.
- Q: What is the difference between traditional red yeast rice and the BP-412 strain?
- A: Traditional strains have over 1000 years of dietary history and confirmed safety, while BP-412 is an industrial strain created by mutagenesis in the 2000s with potential unknown metabolites.